OBJECTIVE: Although smoking is a risk factor for cardiovascular and rheumatic disease severity, only 10% of rheumatology visits document cessation counseling. After implementing a rheumatology clinic protocol that increased tobacco quitline referrals 20-fold, we undertook this study to examine patients' barriers and facilitators to smoking cessation based on prior rheumatology experiences, to solicit reactions to the new cessation protocol, and to identify patient-centered outcomes or signs of cessation progress following improved care. METHODS: We recruited 19 patients who smoke (12 with rheumatoid arthritis [RA] and 7 with systemic lupus erythematosus [SLE]) to participate in 1 of 3 semistructured focus groups. Transcripts of the focus group discussions were analyzed using thematic analysis to classify barriers, facilitators, and signs of cessation progress. RESULTS: Participant-reported barriers and facilitators to cessation involved psychological, health-related, and social and economic factors, as well as health care messaging and resources. Commonly discussed barriers included viewing smoking as a crutch amid rheumatic disease, rarely receiving cessation counseling in rheumatology clinics, and very limited awareness that smoking can worsen rheumatic diseases or reduce efficacy of some rheumatic disease medications. Participants endorsed our cessation protocol with rheumatology-specific education and accessible resources, such as a quitline. Beyond quitting, participants prioritized knowing why and how to quit as signs of progress outcomes. CONCLUSION: Focus groups identified themes and categories of facilitators/barriers to smoking cessation at the levels of patient and health system. Two key outcomes of improving cessation care for patients with RA and SLE were knowing why and how to quit. Emphasizing rheumatologic health benefits and cessation resources is essential when designing and evaluating rheumatology smoking cessation interventions.
OBJECTIVE: Although smoking is a risk factor for cardiovascular and rheumatic disease severity, only 10% of rheumatology visits document cessation counseling. After implementing a rheumatology clinic protocol that increased tobacco quitline referrals 20-fold, we undertook this study to examine patients' barriers and facilitators to smoking cessation based on prior rheumatology experiences, to solicit reactions to the new cessation protocol, and to identify patient-centered outcomes or signs of cessation progress following improved care. METHODS: We recruited 19 patients who smoke (12 with rheumatoid arthritis [RA] and 7 with systemic lupus erythematosus [SLE]) to participate in 1 of 3 semistructured focus groups. Transcripts of the focus group discussions were analyzed using thematic analysis to classify barriers, facilitators, and signs of cessation progress. RESULTS:Participant-reported barriers and facilitators to cessation involved psychological, health-related, and social and economic factors, as well as health care messaging and resources. Commonly discussed barriers included viewing smoking as a crutch amid rheumatic disease, rarely receiving cessation counseling in rheumatology clinics, and very limited awareness that smoking can worsen rheumatic diseases or reduce efficacy of some rheumatic disease medications. Participants endorsed our cessation protocol with rheumatology-specific education and accessible resources, such as a quitline. Beyond quitting, participants prioritized knowing why and how to quit as signs of progress outcomes. CONCLUSION: Focus groups identified themes and categories of facilitators/barriers to smoking cessation at the levels of patient and health system. Two key outcomes of improving cessation care for patients with RA and SLE were knowing why and how to quit. Emphasizing rheumatologic health benefits and cessation resources is essential when designing and evaluating rheumatology smoking cessation interventions.
Authors: Wendy Cozen; David Diaz-Sanchez; W James Gauderman; John Zadnick; Myles G Cockburn; Parkash S Gill; Rizwan Masood; Ann S Hamilton; Minna Jyrala; Thomas M Mack Journal: J Clin Immunol Date: 2004-11 Impact factor: 8.317
Authors: Antonio Naranjo; Ana Bilbao; Celia Erausquin; Soledad Ojeda; Félix M Francisco; Iñigo Rúa-Figueroa; Carlos Rodríguez-Lozano Journal: Rheumatol Int Date: 2013-09-05 Impact factor: 2.631
Authors: Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder Journal: MMWR Morb Mortal Wkly Rep Date: 2016-11-11 Impact factor: 17.586
Authors: Iris Navarro-Millán; Christina Charles-Schoeman; Shuo Yang; Joan M Bathon; S Louis Bridges; Lang Chen; Stacey S Cofield; Louis J Dell'Italia; Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis Journal: Arthritis Rheum Date: 2013-06
Authors: Michelle Tong; Andrea Gilmore-Bykovskyi; Laura Block; Edmond Ramly; Douglas W White; Monica L Messina; Christie M Bartels Journal: J Clin Rheumatol Date: 2022-06-12 Impact factor: 3.902
Authors: Maria Schletzbaum; Xing Wang; Robert Greenlee; Megan E Piper; Christie M Bartels Journal: Arthritis Care Res (Hoboken) Date: 2021-05 Impact factor: 4.794
Authors: Christie M Bartels; Lauren Johnson; Edmond Ramly; Daniel J Panyard; Andrea Gilmore-Bykovskyi; Heather M Johnson; Patrick McBride; Zhanhai Li; Emmanuel Sampene; Diane R Lauver; Kristin Lewicki; Megan E Piper Journal: Arthritis Care Res (Hoboken) Date: 2022-05-27 Impact factor: 5.178
Authors: Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond Journal: Front Immunol Date: 2020-07-02 Impact factor: 7.561
Authors: Maud Wieczorek; James Martin Gwinnutt; Maxime Ransay-Colle; Suzanne Mm Verstappen; Francis Guillemin; Andra Balanescu; Heike Bischoff-Ferrari; Annelies Boonen; Giulio Cavalli; Savia de Souza; Annette de Thurah; Thomas Ernst Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja A Stamm; Karen Walker-Bone; Joep Welling; Mirjana Zlatkovic-Svenda Journal: RMD Open Date: 2022-03